IMPLANET signs an exclusive distribution agreement for SMTP Technology Co.’s Ultrasonic Surgical Scalpel in France

  • SMTP Technology Co., a subsidiary of Sanyou Medical, is a Chinese company specializing in the manufacture and marketing of medical ultrasound equipment
  • Exclusive distribution agreement for healthcare institutions in France

November 23, 2022

BORDEAUX, France & BOSTON–(BUSINESS WIRE)-Regulatory News:

IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME stock savings plans) (Paris: ALIMP), a medical device company specializing in spinal implants, announces today the signing of an agreement with SMTP Technology Co., a high-tech medical device company specializing in specializes in the manufacture and marketing of medical ultrasound equipment, for the exclusive distribution in France of its latest generation surgical ultrasound scalpel.

Adam Li, GMA & International Business Manager at SMTP Technology Co.explained: “We are delighted to have signed this contract, which binds us to IMPLANET, which will henceforth ensure the distribution of our latest generation ultrasonic surgical scalpel. This innovative solution increases surgical efficiency while increasing patient safety. Thanks to this collaboration with IMPLANET, a company known for its expertise in the field of spinal surgery and its presence in French medical centers, we strengthen the credibility of our solutions for their international use“.

Ludovic Lastennet, Chief Executive Officer of IMPLANETadded: “This latest contract, coming immediately after the commercial and technological partnership with Sanyou Medical, underscores the relevance of our repositioning in the spine market. The surgical scalpel developed by SMTP aims to meet the needs of surgeons and patients alike through its innovation and ease of use. IMPLANET is proud to work with one of the few companies in the world capable of developing this type of ultrasound-based product“.

The ultrasonic surgical scalpel developed by SMTP Technology Co. can support open surgery as well as minimally invasive surgery and endoscopic intervertebral surgery. Approved in China, the European Union and the United States, this product features an innovative design that guarantees increased surgical safety. Thanks to the smaller amplitude of its cutting tip, the scalpel cuts through bone tissue by accelerating hundreds of thousands of mechanical oscillations per second, while being gentle on soft tissue.

The agreement signed today between IMPLANET and SMTP Technology Co. follows the signing of the distribution agreement and technology partnership with Sanyou Medical, of which SMTP Technology Co. is a subsidiary. This new agreement gives IMPLANET the exclusive rights to distribute the scalpel on the French market.

Upcoming financial publication

  • Annual turnover 2022on January 17, 2023 Aftermarket

About SMTP Technology Co.

Established in 2010, SMTP Technology Co. is a high-tech medical device company focusing on the innovative R&D, manufacturing and marketing of ultrasonic surgical equipment. The ultrasonic osteotomy surgical system manufactured by SMTP Technology, which supports both open surgery and minimally invasive surgery under the canal and intervertebral endoscope, has received market approval in China, the European Union and the United States. Located in the Zhangjiagang Free Trade Zone in Jiangsu Province, SMTP is a subsidiary of the Sanyou Group with 100 employees and a turnover of EUR 14 million.

For more information, visit the company’s website at http://www.tpmedical.com/profile_en.html

About IMPLANETS

IMPLANET is a medical technology company founded in 2007 that manufactures high-quality implants for orthopedic surgery. Its activity revolves around a comprehensive innovative solution to improve the treatment of spinal pathologies (JAZZ®), complemented by the Orthopedic & Spine Development (OSD) product range, acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates) . Implanet’s proven orthopedic platform is based on the traceability of its products. JAZZ® is protected by four families of international patents and has received 510(k) clearance from the Food and Drug Administration (FDA) in the United States, CE Mark in Europe and ANVISA clearance in Brazil. IMPLANET employs 39 people and achieved a consolidated turnover of 6.1 million euros in 2021. Based near Bordeaux, France, IMPLANET opened a US office in Boston in 2013. IMPLANET is listed on the Euronext growth market in Paris. Visit www.implanet.com for more information.

contacts

IMPLANETS
Ludovic Lastennet, CEO
David Dieumegard, Chief Financial Officer
Tel : +33 (0)5 57 99 55 55
[email protected]

newcap
Investor Relations
Mathilde Boehn
Nicholas Fossiez
Tel.: +33 (0)1 44 71 94 94
[email protected]

newcap
Media Relations
Arthur Rouille
Tel.: +33 (0)1 44 71 94 94
[email protected]

Source

Leave a Reply

Your email address will not be published. Required fields are marked *